Elsa U. Pardee Foundation

Elsa U. Pardee Foundation

The foundation was established in 1944 by Elsa U. Pardee, whose late husband James T. Pardee served as chairman of Dow Chemical Company, providing the chemical-industry wealth that endows the institution. It operates from Midland, Michigan, sharing administrative resources and board members with the Rollin M. Gerstacker Foundation, a sister entity deeply embedded in the same corporate lineage. Gail E. Lanphear serves as president, maintaining the Pardee family's direct operational involvement nearly eight decades after founding. Grant-making concentrates on novel cancer research, funding projects that investigate new approaches to treatment and cure. The foundation backs academic medical centers and independent laboratories, prioritizing proposals with the potential to shift clinical practice rather than incremental studies. Historical giving patterns show a preference for seed-stage research that lacks NIH funding, effectively operating as a philanthropic venture investor in oncology. Geographic reach spans the United States, with no disclosed bias toward any single research institution. The internal investment portfolio, managed from Midland, provides the grant-making corpus. No public AUM figure exists; the foundation discloses neither total assets nor annual payout rates. Board composition offers a window into governance: former Michigan Attorney General Bill Schuette serves as trustee, while Dr. Michael Woolhiser chairs the medical committee that vets scientific proposals. The Council of Michigan Foundations lists the entity as a member, connecting it to state-level philanthropic coordination but revealing no further operational scale. The Pardee Foundation is structurally distinct for its co-location and shared governance with the Rollin M. Gerstacker Foundation — a configuration that pools administrative overhead across two separate Dow-family legacies without merging their distinct charitable missions. This shared-services model from a single Midland office allows both foundations to direct a higher fraction of investment returns toward grant-making rather than operations, a quiet structural efficiency uncommon among standalone endowed foundations of comparable vintage.